--- title: "Texas Capital Bancshrs Pref Share TCBIO 5.75 Perp 06/15/26 B | 8-K: FY2026 Q1 Revenue: USD 323.99 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/283807012.md" datetime: "2026-04-23T10:07:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283807012.md) - [en](https://longbridge.com/en/news/283807012.md) - [zh-HK](https://longbridge.com/zh-HK/news/283807012.md) generator: "portal-rs" --- # Texas Capital Bancshrs Pref Share TCBIO 5.75 Perp 06/15/26 B | 8-K: FY2026 Q1 Revenue: USD 323.99 M Revenue: As of FY2026 Q1, the actual value is USD 323.99 M. EPS: As of FY2026 Q1, the actual value is USD 1.56. EBIT: As of FY2026 Q1, the actual value is USD -160.3 M. #### Net Income GAAP net income to common was $69.5 million, an increase of $26.7 million or 63% compared to Q1 2025. Adjusted net income to common was $70.5 million, up $27.8 million or 65% year-over-year. #### Pre-Provision Net Revenue (PPNR) GAAP PPNR was $110.4 million, increasing $33.0 million or 43% year-over-year. Adjusted PPNR was $111.8 million, an increase of $34.4 million or 44% compared to Q1 2025. #### Revenue Net Interest Income for Q1 2026 was $254.7 million, compared to $236.0 million in Q1 2025. Non-Interest Revenue was $69.3 million in Q1 2026, up from $44.4 million in Q1 2025. Total Adjusted Revenue was $324.0 million in Q1 2026, compared to $280.5 million in Q1 2025. Non-interest income increased $24.8 million or 56% year-over-year to $69.3 million, representing 21% of total revenue. #### Operational Metrics Non-Interest Expense (Adjusted) for Q1 2026 was $212.2 million, compared to $203.0 million in Q1 2025. Provision for Credit Losses was $16.0 million in Q1 2026, compared to $17.0 million in Q1 2025. Income Tax Expense (Adjusted) was $21.0 million in Q1 2026, compared to $13.4 million in Q1 2025. Preferred Stock Dividends remained constant at $4.3 million in both Q1 2026 and Q1 2025. #### Unique Metrics Investment Banking, Private Wealth, and Treasury Product Fees totaled $58.8 million, growing $21.8 million or 59%. Investment banking and trading income reached a record high of $42.3 million. Treasury product fees increased 14% year-over-year to a record high of $12.1 million. Wealth management fees grew 11% year-over-year to a record $4.4 million, supported by AUM growth of 16% year-over-year to $4.4 billion. Book value per share reached $75.71, an increase of $7.71 or 11%. Tangible book value per share was $75.67, up $7.70 or 11%, marking an all-time high for the Firm. Adjusted Earnings per Share (EPS) grew $0.66 or 72% year-over-year to $1.58. Adjusted Return on Average Assets (ROAA) was 0.97%, a 36bps improvement year-over-year. Commercial loan balances increased $1.2 billion or 10% year-over-year, contributing to a total loan growth of $2.8 billion. The Firm repurchased $75 million or 770 thousand shares in Q1 2026. The total Allowance for Credit Losses (ACL) as a percentage of Loans Held for Investment (LHI) stood at 1.32%, and 1.81% when excluding mortgage finance. Quarterly Net Charge-offs totaled $17.4 million or 30bps of average LHI. Criticized Loans as a percentage of Total LHI declined 6bps quarter-over-quarter to 2.58%. The net interest margin was 3.43%, up 24bps. Common Equity / Total Assets was 9.87%, a decrease of 11bps. Tangible Common Equity / Tangible Assets was 9.87%, down 10bps. #### Balance Sheet Highlights Total Assets were $33,486 million, up 7% year-over-year. Cash and Equivalents were $2,957 million, a decrease of -22% year-over-year. Debt & Equity Securities were $4,673 million, up 3% year-over-year. Commercial Loans reached $12,499 million, up 10% year-over-year. Mortgage Finance Loans were $6,962 million, up 47% year-over-year. Total LHI was $25,180 million, up 13% year-over-year. Allowance for Credit Losses on Loans was - $270 million, down -3% year-over-year. Total Deposits were $28,517 million, up 9% year-over-year. Non-Interest Bearing Deposits were $7,635 million, down -3% year-over-year. Interest Bearing Deposits were $20,882 million, up 15% year-over-year. Short-Term Borrowings were $0 million, down -100% year-over-year. Total Liabilities were $29,880 million, up 7% year-over-year. Total Shareholder’s Equity was $3,606 million, up 5% year-over-year. #### Loan Portfolio and Deposit Composition Total LHI increased $2.8 billion or 13% year-over-year to $25.2 billion. Ending period commercial loans increased $1.2 billion or 10% year-over-year to $12.5 billion. Commercial real estate loans declined modestly to $5.3 billion, down -2% quarter-over-quarter. Average mortgage finance loans declined -11% quarter-over-quarter to $5.2 billion. Period end total deposit balances increased $2.5 billion or 9% year-over-year. The average cost of interest bearing deposits declined by 15bps to 3.32%. #### Asset Quality Total ACL was $331.5 million. Total ACL, excluding mortgage finance (MF9), increased $2.3 million quarter-over-quarter to $328.9 million. Net charge-offs were $17.4 million, or 0.30% of average LHI. Quarterly provision expense as a percentage of average LHI was 28bps, and 36bps when excluding MF9. Criticized LHI declined $112 million or -15% year-over-year, with its percentage of total LHI declining 83bps to 2.58%. Non-performing assets represented 50 basis points of total assets, with a $28 million quarter-over-quarter increase. #### Regulatory Capital Levels The Common Equity Tier 1 (CET1) ratio was 11.99%. The Tier 1 Capital ratio was 12.13%. The Total Capital ratio was 15.93%. Tangible common equity to tangible assets was 9.87%. The Firm issued $400 million of fixed-to-floating rate senior notes at 5.30% due in 2032. The Firm expects to redeem $375 million of holding company subordinated notes in the second quarter. #### 2026 Guidance For Full Year 2026, Total Adjusted Revenue is expected to see mid to high single-digit percentage growth compared to Full Year 2025. Adjusted Non-Interest Expense is projected to have mid single-digit percentage growth, and the Provision / Average LHI (Excluding Mortgage Finance LHI) is anticipated to be between 35bps - 40bps. The CET1 Ratio is expected to be greater than 11%, and the tax rate is estimated at approximately 25% for the full year. ### Related Stocks - [TCBIO.US](https://longbridge.com/en/quote/TCBIO.US.md) ## Related News & Research - [Nuburu announces 1-for-40 reverse stock split effective Sept. 1, 2026](https://longbridge.com/en/news/297558878.md) - [Vuxen Group announces availability of FY2025/2026 annual report (May 1, 2025–April 30, 2026)](https://longbridge.com/en/news/297499193.md) - [Systemair corrects dividend record date to Aug. 31, 2026 from Sept. 31 error](https://longbridge.com/en/news/297344953.md) - [iShares Core S&P 500 ETF declares Q3 2026 distribution of R$ 0.10 per unit](https://longbridge.com/en/news/297548335.md) - [AgroGalaxy delays 2025 results release to Nov. 30, 2026](https://longbridge.com/en/news/297440664.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**